Lurbinectedin is a medication that is used for the treatment of certain types of cancer. However, there is limited information available specifically regarding its effects on unborn children. It is important to consult with a healthcare professional for personalized advice and guidance in this matter.

According to the drug patent information provided by Drug Patent Watch, there is no specific mention of the potential harm to unborn children associated with lurbinectedin [1]. However, this information alone may not be sufficient to draw a definitive conclusion.

The Mayo Clinic provides information on the precautions to be taken while using lurbinectedin. It states that the medication should not be used during pregnancy unless the potential benefits outweigh the risks. This suggests that there may be potential risks to the unborn child [2]. The Mayo Clinic also recommends the use of effective contraception during treatment with lurbinectedin to prevent pregnancy [2].

The official website for Zepzelca, the brand name for lurbinectedin, does not provide specific information about the effects of lurbinectedin on unborn children [3]. However, it does mention that the drug should not be used during pregnancy unless the potential benefits outweigh the risks [3].

In conclusion, the available information suggests that lurbinectedin may pose potential risks to unborn children. It is important to consult with a healthcare professional for personalized advice and guidance if you are pregnant or planning to become pregnant while using lurbinectedin.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from: https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Mayo Clinic. Lurbinectedin (Intravenous Route) - Precautions. Retrieved from: https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/precautions/drg-20490804
[3] Zepzelca. Zepzelca® (lurbinectedin) for injection. Retrieved from: https://www.zepzelca.com/